Editorial
|
|
|
|
|
Patients should not participate in non-inferiority trials
|
|
|
|
New Products
|
|
|
|
|
More evaluation needed
|
|
|
|
|
|
|
|
|
|
Not acceptable. Dimethyl sulfoxide is best
|
|
|
|
|
|
|
|
|
|
|
|
Possibly helpful in some cases
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Just another echinocandin
|
|
|
|
|
|
|
|
|
|
|
|
Approval finally not granted
|
|
|
|
|
|
|
|
|
|
Other treatments are preferable
|
|
|
|
|
|
|
|
|
|
|
|
Cutaneous T cell lymphoma: for rare patients
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No advantage and less convenient
|
|
|
|
Adverse Effects
|
|
|
|
|
Rare, sometimes fatal and mostly drug-induced
|
|
|
|
|
|
|
|
|
|
Relatively reassuring data
|
|
|
|
|
|
|
|
|
|
Patients treated for osteoporosis are especially at risk.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Miscarriage and birth defects
|
|
|
|
|
|
|
|
|
|
|
|
The French experience after 6 months
|
|
|
|
Reviews
|
|
|
|
|
Diagnosis and management
|
|
|
|
|
|
|
|
|
|
|
|
Key information for healthcare professionals and the public
|
|
|
|
|
|
|
|
|
|
Choosing the most appropriate treatment is tricky
|
|
|
|
|
|
Outlook
|
|
|
|
|
An unprecedented move
|
|
|
|
|
|
|
|
|
|
|
|
More rapid market access, but less thorough evaluation
|
|
|
|
|
|
|
|
|
|
Many women are not aware that common drugs can harm their unborn child
|
|
|
|
|
|
|
|
|
|
|
|